ITALY, Torino, Mar, 03, 2020. ELITechGroup is pleased to announce the release of the GeneFinderTM COVID-19 Plus RealAmp Kit by OSANGHealthcare. The Kit is CE-IVD certified and detects SARS-CoV-2 on all major PCR cyclers as well as on the Sample-to Result-Platform ELITe InGenius® The test will complement the menu of 37 CE-IVD certified infectious disease tests already available on ELITe InGenius® The SARS-CoV-2 test was developed by OSANGHealthcare of Korea to provide a fast and easy-to-use diagnostic solution to contain the expansion of the virus and to rapidly identify clusters of infection. The kit detects the RdRP gene, E gene and N gene and is in full compliance with the WHO Guidelines. The endogenous Internal Control allows to confirm the quality of the sample material extracted. ELITechgroup and OSANGHealthcare collaborate to provide molecular diagnostics solutions for screening and diagnosis of patients even in epidemic situations. Mr Roberto Meda, Vice President MDx ELITechGroup, and Mr Sam Cho, Executive Vice President, Chief Marketing Officer of OSANGHealthcare are excited to offer the first Sample-to-Result solution for the detection of the SARS-CoV-2 virus. The rapid availability of such a solution was made possible by the dedication and close collaboration between the teams of the two companies. About ELITechGroup: ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor in advancing clinical diagnostics to laboratories in the proximity market, those operating closer to the patient. About OSANG Healthcare: OSANG Healthcare is a manufacturer of IVD (In-Vitro Diagnostics) Medical Devices of multiple fields ranging from Biochemistry, Immunoassay, and Molecular Diagnostics distributing globally to 100+ countries for over 23 years. By utilizing our in house innovation, OSANG Healthcare is dedicated to providing the most accurate, affordable, and real-time results at Point-of-Care (POC)
ELITechGroup Announces Regulatory Approval of its Blood Borne Virus Panel in Japan
ELITechGroup’s blood-borne virus (BBV) panel received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) The ELITe BBV panel was launched in 2022 and comprises three quantitative IVD assays targeting Human Immunodeficiency virus-1 (HIV-1), Human Hepatitis B Virus (HBV), and Human Hepatitis C Virus (HCV) Turin, June 13, 2024: ELITechGroup…